NCT06149169 2024-08-21
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2 Unknown
Clinical Trials
361 trialsNCT06078306 2024-04-22
CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT02232516 2024-04-10
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
Northwestern University
Phase 2 Unknown
NCT06033820 2024-03-13
Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL
RenJi Hospital
Phase 2 Unknown
NCT02242097 2024-03-12
Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma
Northwestern University
Phase 2 Unknown
NCT06290817 2024-03-04
Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT05875428 2024-02-08
Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Unknown
NCT04731974 2024-02-07
Acute Concussion and Melatonin
Children's National Research Institute
Phase 2 Unknown
NCT06201507 2024-01-12
BV-AVD-R Treatment Children Hodgkin's Lymphoma
Beijing Children's Hospital
Phase 2 Unknown
NCT05590221 2024-01-08
Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT04263584 2024-01-05
COPA-R-CHOP
University Hospital Muenster
Phase 2 Unknown
NCT05757466 2023-12-19
Prolgo-HL
St. Petersburg State Pavlov Medical University
Phase 2 Unknown
NCT03617666 2023-12-12
AVENuE
University College, London
Phase 2 Unknown
NCT03341520 2023-11-30
GAZAI
Heidelberg University
Phase 2 Unknown
NCT04089215 2023-11-24
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2 Unknown
NCT06141304 2023-11-21
Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT
The First Hospital of Jilin University
Phase 2 Unknown
NCT04758650 2023-11-18
MITRAS
Universitair Ziekenhuis Brussel
Phase 2 Unknown
NCT05978739 2023-10-25
Evaluating Different Doses of Orelabrutinib in MCL
InnoCare Pharma Inc.
Phase 2 Unknown
NCT05290090 2023-10-17
ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT06074107 2023-10-11
Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects
BeBetter Med Inc
Phase 2 Unknown
NCT04754035 2023-10-03
IMPROVE
IRCCS San Raffaele
Phase 2 Unknown
NCT04888741 2023-09-28
MoTD
University of Birmingham
Phase 2 Unknown
NCT05979948 2023-09-14
CZ-WM01
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT03249870 2023-09-06
EWALL-INO
Versailles Hospital
Phase 2 Unknown
NCT02471391 2023-08-21
AIM
Peter MacCallum Cancer Centre, Australia
Phase 2 Unknown
NCT03331731 2023-08-21
PLIMATH
Peter MacCallum Cancer Centre, Australia
Phase 2 Unknown
NCT03505554 2023-08-07
CRU3
University of Milano Bicocca
Phase 2 Unknown
NCT05976997 2023-08-04
Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)
Huazhong University of Science and Technology
Phase 2 Unknown
NCT05871684 2023-08-01
A Combination Study of CAR-T Therapy in r/r B-NHL
Ruijin Hospital
Phase 2 Unknown
NCT05887726 2023-07-27
Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors
Liaoning Cancer Hospital & Institute
Phase 2 Unknown
NCT05940051 2023-07-11
Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT05940064 2023-07-11
Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT05576532 2023-06-28
Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Unknown
NCT02396043 2023-06-18
Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma
Sun Yat-sen University
Phase 2 Unknown
NCT04480099 2023-06-13
Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma
Ruijin Hospital
Phase 2 Unknown
NCT03077828 2023-06-02
Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Northwestern University
Phase 2 Unknown
NCT03226249 2023-06-02
PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma
Northwestern University
Phase 2 Unknown
NCT05073250 2023-05-12
IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.
Chinese PLA General Hospital
Phase 2 Unknown
NCT05816746 2023-05-09
Decitabine and Anti-PD-1 in R/R DLBCL
Chinese PLA General Hospital
Phase 2 Unknown
NCT05252403 2023-05-06
Residual Disease Driven Strategy for CARCIK (CD19) in Adults/Pediatric BCP-ALL
Fondazione Matilde Tettamanti Menotti De Marchi Onlus
Phase 2 Unknown
NCT05823701 2023-04-21
Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT05809167 2023-04-12
Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT03688451 2023-03-29
Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma
University of Cincinnati
Phase 2 Unknown
NCT01593488 2023-03-24
CILI
National Cancer Institute, Naples
Phase 2 Unknown
NCT05774028 2023-03-17
Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) in the Treatment of Untreated Early Non-upper Respiratory Tract or Advanced Extranodal NK/T-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT05772624 2023-03-16
Lowdose Nivolumab in Combination With AVD as Front Line Therapy for Classic Hodgkin's Lymphoma
Hospital Universitario Dr. Jose E. Gonzalez
Phase 2 Unknown
NCT05755828 2023-03-06
Clinical Study of Autologous Stem Cell Transplantation + Anti-CD19 CAR T Cells for B-cell Lymphoma
The Affiliated Hospital of Xuzhou Medical University
Phase 2 Unknown
NCT05744037 2023-02-24
Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells
The Affiliated Hospital of Xuzhou Medical University
Phase 2 Unknown
NCT05322330 2023-02-09
Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT04113226 2023-02-08
Relyage
Centre Hospitalier Universitaire, Amiens
Phase 2 Unknown